Humanigen Inc

NASDAQ:HGEN   3:59:53 PM EDT
6.36
0.00 (0.00%)
4:49:26 PM EDT: $6.33 -0.03 (-0.47%)
Products

FDA declines Humanigen's EUA Request for Lenzilumab in Hospitalized COVID Patients

Published: 09/09/2021 04:26 GMT
Humanigen Inc (HGEN) - FDA Has Declined Humanigen’s Emergency Use Authorization (eua) Request for Lenzilumab in Hospitalized Covid-19 Patients.
Humanigen - FDA Has Declined Its Request for Emergency Use Authorization of Lenzilumab to Treat Newly Hospitalized Covid-19 Patients.
Nih's Activ-5/bet-b Study is Expected to Provide Further Data That May Support a New Eua Request.
Humanigen - FDA Stated It Was Unable to Conclude Known&potential Benefits of Lenzilumab Outweigh Known&potential Risks of Use for Covid19 Treatment.